Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

OBJECTIVES: Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc) and are a cause of disease-related morbidity. In an earlier trial, treatment with bosentan, an oral endothelin receptor antagonist, reduced the occurrence of new DUs by 48%. The present study (RAPIDS-2, f...

Full description

Saved in:
Bibliographic Details
Main Authors: Matucci-Cerinic, Marco, Denton, Christopher P, Furst, Daniel E, Mayes, Maureen D, Hsu, Vivien M, Carpentier, Patrick, Wigley, Fredrick M, Black, Carol M, Fessler, Barri J, Merkel, Peter A, Pope, Janet E, Sweiss, Nadera J, Doyle, Mittie K, Hellmich, Bernhard, Medsger, Thomas A, Morganti, Adele, Kramer, Fabrice, Korn, Joseph H, Seibold, James R
Format: Artigo
Language:Inglês
Published: BMJ Group 2010
Subjects:
Clinical and Epidemiological Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3002766/
https://ncbi.nlm.nih.gov/pubmed/20805294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2010.130658
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items